---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-024618"
form_type: "8-K"
ticker: "SHPH"
cik: "0001757499"
company_name: "Shuttle Pharmaceuticals Holdings, Inc."
filed_at: "2025-11-21T23:59:59+00:00"
generated_at: "2026-05-16T17:40:00.834267+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Shuttle Pharma discontinues Ropidoxuridine trial, settles $557K debt for $300K

## Summary
- Settlement with Theradex: $300K payment in full for ~$557K debt; both parties release claims.
- Company discontinues clinical trials of Ropidoxuridine; ends enrollment and begins FDA-compliant winddown.
- Additional ~$750K owed to five hospital research sites under separate agreements.
- Expects majority of winddown costs in Q4 2025; amount still being assessed.
- Interim CEO Christopher Cooper signs filing; trial termination follows Theradex's Oct 15 termination notice.

## SEC filing metadata
- accession: 0001493152-25-024618
- form_type: 8-K
- ticker: SHPH
- cik: 0001757499
- company_name: Shuttle Pharmaceuticals Holdings, Inc.
- filed_at: 2025-11-21T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 1.02, 2.05, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1757499/000149315225024618/0001493152-25-024618-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1757499/000149315225024618/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-024618
- JSON: https://secwatch.observer/filing/0001493152-25-024618.json
- Plain text: https://secwatch.observer/filing/0001493152-25-024618.txt

## Source-grounded claims
- claim_id: 6f30008c7519eec9b9e1cf1efabaed03569f9830
  claim: Shuttle Pharmaceuticals Holdings, Inc. announced a restructuring affecting clinical trials of Ropidoxuridine.
  evidence_excerpt: On November 20, 2025, in light of the foregoing, the Company committed to a plan to discontinue its clinical trials of Ropidoxuridine (the “Clinical Trials”), as provided for under the Master Agreement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1757499/000149315225024618/0001493152-25-024618-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.